Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Orexo AB

Market Cap 740M 79.17M 68.13M 62.71M 58.9M 111M 7.49B 112M 289M 3.67B 297M 291M 12.79B P/E Ratio 2026 *
-2.35x
P/E Ratio 2027 * -2.94x
Enterprise Value 542M 58M 49.91M 45.94M 43.15M 81.09M 5.49B 81.98M 211M 2.69B 218M 213M 9.37B EV / Sales 2026 *
20.9x
EV / Sales 2027 * 22.2x
Free-Float
70.1%
Yield 2026 *
-
Yield 2027 * -
1 day-6.25%
3 months-34.98%
6 months-31.15%
Current year-34.98%
Current year 2.1
Extreme 2.1
2.29
1 year 2.02
Extreme 2.02
3.23
3 years 1.08
Extreme 1.08
3.23
5 years 1.04
Extreme 1.04
4.13
10 years 1.04
Extreme 1.04
7.7
Manager TitleAgeSince
Chief Executive Officer 54 05/02/2013
Director of Finance/CFO 59 01/09/2022
Chief Tech/Sci/R&D Officer - 01/10/2024
Director TitleAgeSince
Director/Board Member 64 01/01/2002
Director/Board Member 70 11/04/2019
Director/Board Member 62 01/04/2022
Change 5-day change 1-year change 3-year change Capi.($)
-6.25%-.--% - - 79.51M
+0.23%-3.64%+40.95%+5.27% 284B
-0.49%-3.93%+15.03%-19.58% 66.94B
-2.30%-1.54%+29.01%+103.86% 8.45B
+0.54%+1.65%-3.53%-11.14% 7.81B
-1.66%+7.65%-1.77%+11.15% 4.67B
-0.76%+8.15%-26.48%+39.35% 3.89B
-5.27%+3.33%-20.20%+4.08% 3.32B
-0.64%-2.02%+36.06%+29.74% 2.55B
-2.22%+3.56%+4.29%-22.89% 1.99B
Average -1.88%+0.05%+8.15%+15.54% 42.6B
Weighted average by Cap. -0.05%-3.37%+33.30%+3.20%

Financials

2026 *2027 *
Net sales 26M 2.78M 2.39M 2.2M 2.07M 3.89M 263M 3.93M 10.14M 129M 10.43M 10.21M 449M 27M 2.89M 2.48M 2.29M 2.15M 4.04M 273M 4.08M 10.53M 134M 10.84M 10.61M 466M
Net income -322M -34.44M -29.63M -27.28M -25.62M -48.14M -3.26B -48.68M -126M -1.6B -129M -126M -5.56B -259M -27.7M -23.83M -21.94M -20.61M -38.72M -2.62B -39.15M -101M -1.29B -104M -102M -4.47B
Net Debt -198M -21.17M -18.22M -16.77M -15.75M -29.6M -2B -29.93M -77.2M -983M -79.46M -77.77M -3.42B -142M -15.19M -13.07M -12.03M -11.3M -21.23M -1.44B -21.47M -55.36M -705M -56.99M -55.78M -2.45B
Logo Orexo AB
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
Employees
65
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!